[go: up one dir, main page]

MX2022003663A - Vacunas contra el virus de inmunodeficiencia humana (vih) que comprenden uno o mas antigenos episensus de poblacion. - Google Patents

Vacunas contra el virus de inmunodeficiencia humana (vih) que comprenden uno o mas antigenos episensus de poblacion.

Info

Publication number
MX2022003663A
MX2022003663A MX2022003663A MX2022003663A MX2022003663A MX 2022003663 A MX2022003663 A MX 2022003663A MX 2022003663 A MX2022003663 A MX 2022003663A MX 2022003663 A MX2022003663 A MX 2022003663A MX 2022003663 A MX2022003663 A MX 2022003663A
Authority
MX
Mexico
Prior art keywords
hiv
vaccine
antigen
subject
epigraph
Prior art date
Application number
MX2022003663A
Other languages
English (en)
Inventor
Louis Picker
Klaus Frueh
Eric Bruening
Bette T M Korber
James Theiler
Emily Marshall
Original Assignee
Triad Nat Security Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Triad Nat Security Llc filed Critical Triad Nat Security Llc
Publication of MX2022003663A publication Critical patent/MX2022003663A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/867—Retroviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se proporcionan en la presente vacunas contra el VIH-1 que comprenden un portador y un antígeno episensus de población determinado usando el procedimiento EpiGraph. También se proporcionan vacunas contra el VIH-1 que comprenden un portador, un antígeno episensus de población, y un antígeno personalizado. También se proporcionan métodos para diseñar y producir una vacuna contra el VIH-1 para un sujeto que comprende diseñar antígenos de vacuna para cubrir óptimamente la diversidad dentro de un área geográfica usando una secuencia de aminoácidos de antígeno generada usando el procedimiento EpiGraph, y producir el antígeno de vacuna diseñado. También se proporciona el método para inducir una respuesta de células T de memoria efectoras que comprenden el diseño de la una o más secuencias de aminoácidos EpiGraph, producir una vacuna que comprende la una o más secuencias de aminoácidos EpiGraph y un vector, y administrar la vacuna a un sujeto. Se proporcionan además métodos para tratar VIH-1 en un sujeto que comprende administrar una cantidad efectiva de las vacunas contra el VIH-1 descritas al sujeto en necesidad de la misma.
MX2022003663A 2014-10-03 2017-03-31 Vacunas contra el virus de inmunodeficiencia humana (vih) que comprenden uno o mas antigenos episensus de poblacion. MX2022003663A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462059497P 2014-10-03 2014-10-03
US201462059506P 2014-10-03 2014-10-03

Publications (1)

Publication Number Publication Date
MX2022003663A true MX2022003663A (es) 2022-04-25

Family

ID=55631703

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2017004275A MX391149B (es) 2014-10-03 2015-10-05 Vacunas contra el virus de inmunodeficiencia humana (vih) que comprenden uno o mas antigenos episensus de poblacion.
MX2022003664A MX2022003664A (es) 2014-10-03 2017-03-31 Vacunas contra el virus de inmunodeficiencia humana (vih) que comprenden uno o mas antigenos episensus de poblacion.
MX2022003663A MX2022003663A (es) 2014-10-03 2017-03-31 Vacunas contra el virus de inmunodeficiencia humana (vih) que comprenden uno o mas antigenos episensus de poblacion.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2017004275A MX391149B (es) 2014-10-03 2015-10-05 Vacunas contra el virus de inmunodeficiencia humana (vih) que comprenden uno o mas antigenos episensus de poblacion.
MX2022003664A MX2022003664A (es) 2014-10-03 2017-03-31 Vacunas contra el virus de inmunodeficiencia humana (vih) que comprenden uno o mas antigenos episensus de poblacion.

Country Status (16)

Country Link
US (3) US10894078B2 (es)
EP (1) EP3200878B1 (es)
JP (3) JP2017531693A (es)
KR (1) KR102633096B1 (es)
CN (1) CN108064181A (es)
AU (2) AU2015327797A1 (es)
CA (1) CA2963573C (es)
EA (1) EA201790680A1 (es)
HK (1) HK1254806A1 (es)
IL (1) IL251469B2 (es)
MA (1) MA40783A (es)
MX (3) MX391149B (es)
SG (1) SG11201702729YA (es)
UA (1) UA126890C2 (es)
WO (1) WO2016054654A1 (es)
ZA (1) ZA202206809B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA40783A (fr) 2014-10-03 2017-08-08 Los Alamos Nat Security Llc Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population
US11980663B2 (en) 2015-07-08 2024-05-14 American Gene Technologies International Inc. HIV pre-immunization and immunotherapy
JP7153332B2 (ja) 2016-02-08 2022-10-14 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド Ｈｉｖワクチン接種および免疫療法
AU2017292582C1 (en) * 2016-07-08 2021-11-11 American Gene Technologies International Inc. HIV pre-immunization and immunotherapy
US20210317192A9 (en) * 2019-05-29 2021-10-14 Massachusetts Institute Of Technology Hiv-1 specific immunogen compositions and methods of use
AU2020315598B2 (en) 2019-07-16 2024-12-12 Gilead Sciences, Inc. HIV vaccines and methods of making and using
AU2020342385A1 (en) 2019-08-29 2022-03-31 Triad National Security, Llc Hepatitis B virus vaccines
KR20230131481A (ko) * 2021-01-14 2023-09-13 길리애드 사이언시즈, 인코포레이티드 Hiv 백신 및 이의 사용 방법
TW202311531A (zh) 2021-08-31 2023-03-16 美商維爾生物科技股份有限公司 重組hcmv載體及其用途
TW202436326A (zh) * 2023-02-13 2024-09-16 長怡 王 包含hiv th/ctl 抗原決定位胜肽的疫苗用於預防及治療hiv感染及aids患者
CN116524994B (zh) * 2023-02-20 2026-01-30 中国科学院天津工业生物技术研究所 一种基于贪婪算法的菌株构建排程设计方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI116851B (fi) * 2001-05-03 2006-03-15 Fit Biotech Oyj Plc Ilmentämisvektori, sen käyttöjä ja menetelmä sen valmistamiseksi sekä sitä sisältäviä tuotteita
MXPA04002631A (es) * 2001-09-20 2004-07-08 Glaxo Group Ltd Vacunas de adn optimizadas por codon gag-vih.
AUPR842501A0 (en) 2001-10-23 2001-11-15 Epipop Pty Ltd A method for identification and development of therapeutic agents
US20030190308A1 (en) * 2002-03-19 2003-10-09 Braun Ralph P. Adjuvant
GB0225788D0 (en) * 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
EP1609107A4 (en) * 2003-03-28 2006-08-30 Idm Pharma Inc METHOD FOR IDENTIFYING OPTIMAL PEPTIDE PITOPARIANTS
CA2918585C (en) 2003-09-17 2019-05-21 Duke University Consensus/ancestral immunogens
AU2011203095A1 (en) 2003-09-17 2011-07-21 Duke University Consensus/Ancestral Immunogens
AU2004280630A1 (en) * 2003-10-10 2005-04-21 Powderject Vaccines, Inc. Method
CA2837748C (en) 2004-05-25 2016-03-08 Oregon Health And Science University Siv and hiv vaccination using rhcmv-and hcmv-based vaccine vectors
CA2620874A1 (en) 2005-08-23 2007-03-01 The Regents Of The University Of California Polyvalent vaccine
CA3184778A1 (en) * 2006-07-28 2008-01-31 The Trustees Of The University Of Pennsylvania Hiv consensus envelope sequences and methods for using same
US20110123485A1 (en) * 2007-03-27 2011-05-26 President And Fellows Of Harvard College Viral vectors for delivering vaccines for hiv and other infectious diseases
EP2143035A4 (en) 2007-03-30 2013-01-02 Merck Sharp & Dohme WIDE REPRESENTATIVE ANTIGEN SEQUENCES AND SELECTION PROCEDURES
SMT201800631T1 (it) * 2008-11-18 2019-01-11 Beth Israel Deaconess Medical Ct Inc Vaccini antivirali con immunogenicità cellulare migliorata
US20120135032A1 (en) * 2009-10-08 2012-05-31 Bavarian Nordic A/S Generation of a broad t-cell response in humans against hiv
ES2625406T3 (es) 2010-03-25 2017-07-19 Oregon Health & Science University Glicoproteínas de CMV y vectores recombinantes
TR201802741T4 (tr) 2010-05-14 2018-03-21 Univ Oregon Health & Science Rekombinant hcmv ve rhcmv vektörleri ve bunların kullanımları.
US8557787B2 (en) 2011-05-13 2013-10-15 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic, prognostic and therapeutic uses of long non-coding RNAs for cancer and regenerative medicine
SMT201800284T1 (it) 2011-06-10 2018-07-17 Univ Oregon Health & Science Glicoproteine cmv e vettori ricombinanti
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
ES2718899T3 (es) 2012-03-02 2019-07-05 Us Gov Health & Human Services Método para modificar la jerarquía de inmunodominio de gag del VIH mediante una vacuna de ADN que expresa regiones conservadas
AP2015008634A0 (en) * 2013-01-07 2015-07-31 Beth Israel Hospital Stabilized human immunodeficiency virus 'hiv' env elope 'env' trimer vaccines and methods of using same
LT2964769T (lt) 2013-03-05 2018-12-10 Oregon Health & Science University Citomegalo viruso vektoriai, leidžiantys kontroliuoti ląstelių nukreipimą į taikinį
WO2015128421A1 (en) 2014-02-28 2015-09-03 Crucell Holland B.V. Replicating recombinant adenovirus vectors, compositions, and methods of use thereof
EA039174B1 (ru) 2014-07-16 2021-12-14 Орегон Хелс Энд Сайенс Юниверсити Цитомегаловирус человека, содержащий гетерологичный антиген, способ его получения, полинуклеотид, клетка, композиция и способ индуцирования иммунного ответа (варианты)
MY175620A (en) 2014-09-26 2020-07-02 Beth Israel Deaconess Medical Ct Inc Methods and compositions for inducing protective immunity against human immunodeficiency virus infection
MA40783A (fr) 2014-10-03 2017-08-08 Los Alamos Nat Security Llc Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population
EP3964569A1 (en) 2015-12-15 2022-03-09 Janssen Vaccines & Prevention B.V. Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof

Also Published As

Publication number Publication date
BR112017006865A2 (pt) 2017-12-12
NZ731173A (en) 2024-04-26
JP2021035946A (ja) 2021-03-04
UA126890C2 (uk) 2023-02-22
EP3200878B1 (en) 2025-06-04
US11628215B2 (en) 2023-04-18
US20170319679A1 (en) 2017-11-09
US11554168B2 (en) 2023-01-17
AU2021218141A1 (en) 2021-09-09
ZA202206809B (en) 2023-11-29
MX2017004275A (es) 2018-01-17
AU2015327797A1 (en) 2017-05-11
IL251469B1 (en) 2023-01-01
SG11201702729YA (en) 2017-04-27
EP3200878A4 (en) 2018-05-30
IL251469B2 (en) 2023-05-01
JP7441340B2 (ja) 2024-03-06
MX2022003664A (es) 2022-04-25
AU2021218141B2 (en) 2024-06-06
US20210046174A1 (en) 2021-02-18
EP3200878A1 (en) 2017-08-09
CN108064181A (zh) 2018-05-22
KR20170122711A (ko) 2017-11-06
EA201790680A1 (ru) 2017-11-30
JP2023059272A (ja) 2023-04-26
MX391149B (es) 2025-03-21
US20210046175A1 (en) 2021-02-18
MA40783A (fr) 2017-08-08
WO2016054654A1 (en) 2016-04-07
JP7212020B2 (ja) 2023-01-24
IL251469A0 (en) 2017-05-29
HK1254806A1 (zh) 2019-07-26
CA2963573C (en) 2024-02-06
CA2963573A1 (en) 2016-04-07
US10894078B2 (en) 2021-01-19
KR102633096B1 (ko) 2024-02-02
JP2017531693A (ja) 2017-10-26

Similar Documents

Publication Publication Date Title
ZA202206809B (en) Hiv vaccines comprising one or more population episensus antigens
MX2025009589A (es) Vacunas a base de peptidos, metodos de fabricacion y sus usos para inducir una respuesta inmune
EA201790534A1 (ru) Способы и композиции для ослабления иммунных ответов против вирусного вектора для переноса, предназначенного для генной терапии
MX2019012223A (es) Anticuerpos anti-cd137 y metodos de uso de los mismos.
WO2015142671A3 (en) Influenza virus vectors and uses therefor
MX2018010586A (es) Nanovacuna de activacion de "sting" para inmunoterapia.
MX2016011537A (es) Metodos y composiciones para aumentar una relacion de celulas t efectoras con respecto a las celulas t reguladoras.
MX388410B (es) Modulacion de celulas mieloides estimulantes y no estimulantes.
HUE045993T2 (hu) Emberi immunhiány vírus antigének, vektorok, készítmények és alkalmazásukra szolgáló eljárások
WO2013106834A3 (en) Immunogenic wt-1 peptides and methods of use thereof
EP4043031A3 (en) Zika viral antigen constructs
MX2018004598A (es) Cepas vacunales recombinantes de listeria y métodos para usar las mismas en la inmunoterapia contra el cáncer.
WO2011103417A3 (en) Vectors expressing hiv antigens and gm-csf and related methods for generating an immune response
MX2017004897A (es) Cepas vacunales recombinantes de listeria y metodos para usar las mismas en la inmunoterapia contra el cancer.
PH12016500500A1 (en) A viral vaccine and methods of manufacture thereof
MX2013007918A (es) Peptidos inmunogenicos monomericos y multimericos.
WO2016073595A8 (en) T cells and dendritic cells for polyomavirus therapy
MX2019000215A (es) Composiciones inmunogenicas a base de listeria que comprenden antigenos de proteinas del tumor de wilms y metodos para su uso.
HK1258649A1 (zh) 来自病原体的免疫原性抗原鉴定以及与临床效力的相关性
WO2016191641A3 (en) Methods for enhancing antigen-specific immune responses using combination therapy comprising papillomavirus capsid antigens
MX2016014868A (es) Metodos para secar por congelacion y rehidratar productos biologicos.
WO2016130560A3 (en) Cross-reactive t cell epitopes of hiv, siv, and fiv for vaccines in humans and cats
MA37749A1 (fr) Vaccins contre les virus réassortis de la fièvre catarrhale et de la peste équine
PH12014501795A1 (en) Rota virus subunit vaccines and methods of making and use thereof
WO2016090035A3 (en) Modulators of activin and methods for modulating immune responses and t follicular helper cells